KRAS and lung cancer: Regarding the molecular profile of lung cancer, only one of our ILD patients with non-squamous NSCLC (7%) had a targetable genetic mutation (KRAS G12C), which tended to be lower than that in the non-ILD group (21.5%), without being significant (p = 0.26).